Received Feb 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | Y006509 | — |
A HCP called to inquire about how to administer a second dose of RECCOMBIVAX HB that would be late according to the recommended schedule. The HCP stated a 32 year old patient received their first dose of RECOMBIVAX HB on 08/26/2024 and he was antici; No additional adverse event; This spontaneous report has been received from a nurse regarding a 32-year-old male patient. The patient's pertinent medical history, current conditions, concomitant medications, previous drug reactions or allergies were not reported. On 26-AUG-2024, the patient was vaccinated with the first dose of hepatitis b vaccine (recombinant) suspension for injection (RECOMBIVAX HB), administered as prophylaxis 1 mL (Lot No. Y006509 has been verified to be a valid lot number for [hepatitis b vaccine (recombinant) suspension for injection], expiration date reported and upon internal validation established as 11-FEB-2027 (strength, route and anatomical location of administration and vaccination scheme frequency were not provided). It was stated that the nurse called to inquire about how to administer a second dose of the vaccine that would be late according to the recommended schedule as the patient supposed to come to the clinic to receive his second dose of the vaccine on 26-FEB-2025 (inappropriate schedule of product administration). No additional adverse event (AE) (no adverse event) was reported.